Vortioxetine for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the antidepressant vortioxetine can help people with newly diagnosed glioblastoma when added to standard radiation and chemotherapy. The goal is to see if it improves mood, quality of life, and possibly treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a newly diagnosed glioblastoma (a type of brain cancer) and will receive the standard radiation plus chemotherapy (temozolomide) after surgery
- Your level of daily function is fairly good — a Karnofsky score of at least 70 (you can care for yourself but might not be able to do heavy activities)
- You are not pregnant, breastfeeding, or planning pregnancy, and if you could have children, you agree to use effective birth control during the trial and for 6 months after
- You have no serious depression, bipolar disorder, schizophrenia, or recent thoughts of suicide or harming others
- You have no other active cancers (unless they have been gone without treatment for at least 1 year)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental drug called liposomal transcrocetin (L-TC) to the standard treatment of radiation and temozolomide chemotherapy helps people with newly diagnosed glioblastoma. It aims to see if the combination improves outcomes compared to standard care alone.
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.